Latest Cellectis UCART19 data show ongoing efficacy

In a manuscript published online Wednesday in Science Translational Medicine, scientists said UCART19 from Cellectis S.A. (Euronext:ALCLS; NASDAQ:CLLS) led to remissions within 28 days in two infants

Read the full 273 word article

User Sign In